Hikma Pharmaceuticals Acquires Novugen's US FDA ANDA Approved Trametinib
Shots:
- Hikma has acquired the Novugen's US FDA ANDA approved trametinib tablets and also entered into a commercial agreement with Novugen
- Under the agreement, Hikma will be responsible for all the US sales and marketing of trametinib while Novugen will manufacture and supply them to Hikma. Furthermore, when product is launched Hikma will have 180 days of US generic market sales exclusivity for trametinib
- Trametinib is an orally administered kinase inhibitor medication used to treat melanoma and glioma
Ref: Hikma | Image: Hikma
Related News:- Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
